ALA 1.61% 15.3¢ arovella therapeutics limited

The dawn of a new SUDA, page-9

  1. 8,819 Posts.
    lightbulb Created with Sketch. 1698
    One lucky break doesnt mean he is successful, why any management would considered giving away around 50% of the company, putting them in $10m dollars debt doesnt say he knows what he is doing
    Possible the reason that they couldn't get the deal past ASX was just the fact it wasn't in the best interest of shareholders.
    What deal has Hopper or Baker delivered that has created shareholder value, the fact they have delivered nothing more than the Mitsubishi second deal, this with a company that has failed to progress the first deal.

    The fact Hopper changed the TGA submission and failed to report this, tells you he cares nothing about shareholders, this after reporting he was improving shareholder value and share holder confidence.
    Why did Teva not appear on the list of Suda partners / companies,
    In the announcement, is there something else that Hopper has over looked. (Remember that the Teva MAA was submitted back in 2017) the out come expected in December 2018, here we are June 2020 and nothing.



 
watchlist Created with Sketch. Add ALA (ASX) to my watchlist
(20min delay)
Last
15.3¢
Change
-0.003(1.61%)
Mkt cap ! $160.3M
Open High Low Value Volume
15.5¢ 15.5¢ 15.0¢ $82.79K 539.5K

Buyers (Bids)

No. Vol. Price($)
1 18124 15.0¢
 

Sellers (Offers)

Price($) Vol. No.
15.5¢ 108897 1
View Market Depth
Last trade - 15.46pm 12/07/2024 (20 minute delay) ?
ALA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.